>>Run a large dose ranging trial at the same time as a large randomized trial in earlier line?
Agree, but that's not my only complaint. The whole idea of true 2nd-line is misguided at this point.
Much better to go after 2nd-gen failures (so call it 2.5-line). In other words 2nd-line if a 2nd-gen drug was used as front-line, otherwise 3rd-line. There they could very likely show convincing evidence, while a 1-year trial in true 2nd-line isn't going to convince anyone of long-term safety.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.